8 research outputs found
Analysis of the determinants of positive response to the ESAT6/CFP10 ELISPOT assay and to the TST (n = 247).
<p>Analysis of the determinants of positive response to the ESAT6/CFP10 ELISPOT assay and to the TST (n = 247).</p
Distribution of responses to PHA and ESAT6/CFP10 ELISPOT assays in HIV patients, by CD4 cell count (boxplot showing median, IQR and range) (n = 285).
<p>1A: Distribution of responses to PHA. 1B: Distribution of responses to ESAT6/CFP10.</p
Characteristics of patients included in the cohort, with a detail of those responding and those not responding to ELISPOT PHA positive control.
*<p><i>p</i> value for difference between PHA<100 and PHA≥100 SFC/10<sup>6</sup>.</p
Vaccine efficacy by Cox regression for any parasitaemia and parasitaemia >10 per ml
<p>Vaccine efficacy by Cox regression for any parasitaemia and parasitaemia >10 per ml</p
Kaplan-Meier plots of time to first infection.
<p>(A) First episode of PCR positivity at any threshold for the trial in Senegal. (B). Combined analysis of data from the Senegal and Kenya trials. (C). First episode of PCR positivity at >10 parasites per ml for the trial in Senegal. (D). Combined analysis of data from the Senegal and Kenya trials</p
Pooled vaccine efficacy by Cox regression for the studies in Kenya and Senegal.
<p>Pooled vaccine efficacy by Cox regression for the studies in Kenya and Senegal.</p
Parasite density as measured by PCR for each trial.
<p>Each line represents an individual volunteer. P = PCR testing performed. During the PCR monitoring follow-up period, blood samples were tested by PCR three times a week from day 70 to day 95 and once per week from day 98 to day 119.</p